Differential effects of LHRH and somatostatin analogs on human breast cancer

Steven T. Brower, Andrew V Schally, Thomas W. Redding, Vincent P. Hollander

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have been interested in the possible direct effects of luteinizing hormone releasing hormone (LHRH) and somatostatin (SS) analogs on the growth of human mammary tumor cells. Four recently synthesized peptide hormones including the LHRH agonists d-Trp6-LHRH and zoladex, LHRH antagonists SB30 and SB75, and the somatostatin analog RC 160 were analyzed for their effects on DNA synthesis of MCF-7 breast cancer cells in culture. At 48 hr, d-Trp6-LHRH and SB30 did not show significant effects (dose range, 10-12-10-6 m). However, the combination of these two peptides at 10-10 m produced significant inhibition of 3[H]thymidine incorporation (50% control). At 72 hr in the absence of estradiol-stimulated growth, d-Trp6-LHRH showed inhibition at 10-12 and 10-10 m (P < 0.005 and 0.001). At higher concentrations, no significant inhibition was noted. In contrast to d-Trp6, SB30 (antagonist) showed no inhibition but significant stimulation of DNA synthesis at 10-5 and 10-4 m. In the presence of added estradiol (10-9 m), complete reversal of d-Trp6-LHRH analog inhibition is noted. In contrast, there is persistent stimulation by SB30 (P < 0.001). At 96 hr, d-Trp6-LHRH continued to show maximal inhibition of 70% in the absence of estradiol. SB30 stimulated DNA synthesis 100% at 10-6 m. At 72 hr, the SS analog RC 160 demonstrated significant inhibition (53%) that was similar to d-Trp6 and SB75 peptides. At 96 hr, RC 160 showed a biphasic response of stimulation at 10-12-10-10 m (P < 0.05) and inhibition at or above 10-6 m. These results demonstrate direct effects of LHRH and somatostatin analogs on the in vitro growth of human breast cancer that are analog specific and concentration dependent.

Original languageEnglish
Pages (from-to)6-14
Number of pages9
JournalJournal of Surgical Research
Volume52
Issue number1
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Somatostatin
Gonadotropin-Releasing Hormone
Breast Neoplasms
Estradiol
DNA
Growth
Goserelin
Hormone Antagonists
Peptides
Peptide Hormones
Thymidine
Cell Culture Techniques

ASJC Scopus subject areas

  • Surgery

Cite this

Differential effects of LHRH and somatostatin analogs on human breast cancer. / Brower, Steven T.; Schally, Andrew V; Redding, Thomas W.; Hollander, Vincent P.

In: Journal of Surgical Research, Vol. 52, No. 1, 01.01.1992, p. 6-14.

Research output: Contribution to journalArticle

Brower, Steven T. ; Schally, Andrew V ; Redding, Thomas W. ; Hollander, Vincent P. / Differential effects of LHRH and somatostatin analogs on human breast cancer. In: Journal of Surgical Research. 1992 ; Vol. 52, No. 1. pp. 6-14.
@article{690be87fde2543f1a12d0587d04b2b9d,
title = "Differential effects of LHRH and somatostatin analogs on human breast cancer",
abstract = "We have been interested in the possible direct effects of luteinizing hormone releasing hormone (LHRH) and somatostatin (SS) analogs on the growth of human mammary tumor cells. Four recently synthesized peptide hormones including the LHRH agonists d-Trp6-LHRH and zoladex, LHRH antagonists SB30 and SB75, and the somatostatin analog RC 160 were analyzed for their effects on DNA synthesis of MCF-7 breast cancer cells in culture. At 48 hr, d-Trp6-LHRH and SB30 did not show significant effects (dose range, 10-12-10-6 m). However, the combination of these two peptides at 10-10 m produced significant inhibition of 3[H]thymidine incorporation (50{\%} control). At 72 hr in the absence of estradiol-stimulated growth, d-Trp6-LHRH showed inhibition at 10-12 and 10-10 m (P < 0.005 and 0.001). At higher concentrations, no significant inhibition was noted. In contrast to d-Trp6, SB30 (antagonist) showed no inhibition but significant stimulation of DNA synthesis at 10-5 and 10-4 m. In the presence of added estradiol (10-9 m), complete reversal of d-Trp6-LHRH analog inhibition is noted. In contrast, there is persistent stimulation by SB30 (P < 0.001). At 96 hr, d-Trp6-LHRH continued to show maximal inhibition of 70{\%} in the absence of estradiol. SB30 stimulated DNA synthesis 100{\%} at 10-6 m. At 72 hr, the SS analog RC 160 demonstrated significant inhibition (53{\%}) that was similar to d-Trp6 and SB75 peptides. At 96 hr, RC 160 showed a biphasic response of stimulation at 10-12-10-10 m (P < 0.05) and inhibition at or above 10-6 m. These results demonstrate direct effects of LHRH and somatostatin analogs on the in vitro growth of human breast cancer that are analog specific and concentration dependent.",
author = "Brower, {Steven T.} and Schally, {Andrew V} and Redding, {Thomas W.} and Hollander, {Vincent P.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0022-4804(92)90271-Z",
language = "English",
volume = "52",
pages = "6--14",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Differential effects of LHRH and somatostatin analogs on human breast cancer

AU - Brower, Steven T.

AU - Schally, Andrew V

AU - Redding, Thomas W.

AU - Hollander, Vincent P.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We have been interested in the possible direct effects of luteinizing hormone releasing hormone (LHRH) and somatostatin (SS) analogs on the growth of human mammary tumor cells. Four recently synthesized peptide hormones including the LHRH agonists d-Trp6-LHRH and zoladex, LHRH antagonists SB30 and SB75, and the somatostatin analog RC 160 were analyzed for their effects on DNA synthesis of MCF-7 breast cancer cells in culture. At 48 hr, d-Trp6-LHRH and SB30 did not show significant effects (dose range, 10-12-10-6 m). However, the combination of these two peptides at 10-10 m produced significant inhibition of 3[H]thymidine incorporation (50% control). At 72 hr in the absence of estradiol-stimulated growth, d-Trp6-LHRH showed inhibition at 10-12 and 10-10 m (P < 0.005 and 0.001). At higher concentrations, no significant inhibition was noted. In contrast to d-Trp6, SB30 (antagonist) showed no inhibition but significant stimulation of DNA synthesis at 10-5 and 10-4 m. In the presence of added estradiol (10-9 m), complete reversal of d-Trp6-LHRH analog inhibition is noted. In contrast, there is persistent stimulation by SB30 (P < 0.001). At 96 hr, d-Trp6-LHRH continued to show maximal inhibition of 70% in the absence of estradiol. SB30 stimulated DNA synthesis 100% at 10-6 m. At 72 hr, the SS analog RC 160 demonstrated significant inhibition (53%) that was similar to d-Trp6 and SB75 peptides. At 96 hr, RC 160 showed a biphasic response of stimulation at 10-12-10-10 m (P < 0.05) and inhibition at or above 10-6 m. These results demonstrate direct effects of LHRH and somatostatin analogs on the in vitro growth of human breast cancer that are analog specific and concentration dependent.

AB - We have been interested in the possible direct effects of luteinizing hormone releasing hormone (LHRH) and somatostatin (SS) analogs on the growth of human mammary tumor cells. Four recently synthesized peptide hormones including the LHRH agonists d-Trp6-LHRH and zoladex, LHRH antagonists SB30 and SB75, and the somatostatin analog RC 160 were analyzed for their effects on DNA synthesis of MCF-7 breast cancer cells in culture. At 48 hr, d-Trp6-LHRH and SB30 did not show significant effects (dose range, 10-12-10-6 m). However, the combination of these two peptides at 10-10 m produced significant inhibition of 3[H]thymidine incorporation (50% control). At 72 hr in the absence of estradiol-stimulated growth, d-Trp6-LHRH showed inhibition at 10-12 and 10-10 m (P < 0.005 and 0.001). At higher concentrations, no significant inhibition was noted. In contrast to d-Trp6, SB30 (antagonist) showed no inhibition but significant stimulation of DNA synthesis at 10-5 and 10-4 m. In the presence of added estradiol (10-9 m), complete reversal of d-Trp6-LHRH analog inhibition is noted. In contrast, there is persistent stimulation by SB30 (P < 0.001). At 96 hr, d-Trp6-LHRH continued to show maximal inhibition of 70% in the absence of estradiol. SB30 stimulated DNA synthesis 100% at 10-6 m. At 72 hr, the SS analog RC 160 demonstrated significant inhibition (53%) that was similar to d-Trp6 and SB75 peptides. At 96 hr, RC 160 showed a biphasic response of stimulation at 10-12-10-10 m (P < 0.05) and inhibition at or above 10-6 m. These results demonstrate direct effects of LHRH and somatostatin analogs on the in vitro growth of human breast cancer that are analog specific and concentration dependent.

UR - http://www.scopus.com/inward/record.url?scp=0026584794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026584794&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(92)90271-Z

DO - 10.1016/0022-4804(92)90271-Z

M3 - Article

VL - 52

SP - 6

EP - 14

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -